original ) (raw )Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
Amichay Meirovitz
EJNMMI Physics
View PDFchevron_right
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study
Francois-Alexandre Buteau
European Journal of Nuclear Medicine and Molecular Imaging, 2017
View PDFchevron_right
Dosimetry in Peptide radionuclide receptor therapy: a review
Marta Cremonesi
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006
View PDFchevron_right
Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule
Felix Mottaghy
EJNMMI Research, 2016
View PDFchevron_right
Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy
Felix Mottaghy
Cancer Biotherapy and Radiopharmaceuticals, 2016
View PDFchevron_right
Dose response of pancreatic neuroendocrine tumours treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE
Mattias Sandström
View PDFchevron_right
Study the effect of the physiological parameters to the optimal administration of lysine/arginine during peptide receptor radionuclide therapy (PPRT) using a physiologically-based pharmacokinetic (PBPK) model
M Luthfy
PROCEEDINGS OF THE INTERNATIONAL CONFERENCE AND SCHOOL ON PHYSICS IN MEDICINE AND BIOSYSTEM (ICSPMB): Physics Contribution in Medicine and Biomedical Applications
View PDFchevron_right
A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours
Nick Reynaert
Physica Medica
View PDFchevron_right
[Peptide receptor radionuclide therapy of neuroendocrine tumors]
Anne Arveschoug
Ugeskrift for laeger, 2009
View PDFchevron_right
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John Zaknun
European Journal of Nuclear Medicine and Molecular Imaging, 2013
View PDFchevron_right
Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE
Anders Sundin
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015
View PDFchevron_right
Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors
E. Grassi
BioMed research international, 2013
View PDFchevron_right
Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
Faozi Artoul
EJNMMI Physics, 2018
View PDFchevron_right
Calculation of absorbed dose due to the 90Y-DOTATOC peptide receptor radionuclide therapy by MCNP5/X
Dragoslav Nikezic
Nuclear Technology and Radiation Protection, 2018
View PDFchevron_right
Peptide receptor radionuclide therapy of neuroendocrine tumors: Case series
Jann Mortensen
Archive of Oncology, 2012
View PDFchevron_right
Dosimetry For 90Y-DOTATOC Therapies in Patients with Neuroendocrine Tumors
Glenn Flux
Cancer Biotherapy and Radiopharmaceuticals, 2007
View PDFchevron_right
First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
Helmut Maecke
Journal of Nuclear Medicine, 2021
View PDFchevron_right
The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
Grace Kong
European Journal of Nuclear Medicine and Molecular Imaging, 2012
View PDFchevron_right
Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs
Stanislas Pauwels
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005
View PDFchevron_right
Peptide Receptor Radionuclide Therapy & Oncology
Hendrik Bergsma
2017
View PDFchevron_right
Clinical Study Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors
G. Pedroli
2016
View PDFchevron_right
Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT/CT study
Amichay Meirovitz
EJNMMI Physics
View PDFchevron_right
A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu
Mark Konijnenberg
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004
View PDFchevron_right
Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience
Dramane Konate
PloS one, 2024
View PDFchevron_right
Monitoring and Predicting Response to Peptide Receptor Radionuclide Therapy: A Quantitative SPECT-CT Based Analysis~!2009-12-10~!2010-02-04~!2010-04-21~!
Guillaume Nicolas
The Open Nuclear Medicine Journal, 2010
View PDFchevron_right
Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead
stephan walrand
International Journal of Molecular Sciences, 2021
View PDFchevron_right
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
Stefano Severi
OncoTargets and Therapy, 2017
View PDFchevron_right
{"__content__"=>"Feasibility of simplifying renal dosimetry in Lu peptide receptor radionuclide therapy.", "sup"=>{"__content__"=>"177"}}
Peter Bernhardt
EJNMMI physics, 2018
View PDFchevron_right
{"__content__"=>"Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.", "sup"=>{"__content__"=>"90"}}
Thomas O'Dorisio
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018
View PDFchevron_right
Study of the most important physiologic parameter using GSA with sobol method and a PBPK model for individualization of peptide-receptor radionuclide therapy
luthfy dzikrillah
2021
View PDFchevron_right
Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy
Sofie Van Binnebeek
European Journal of Nuclear Medicine and Molecular Imaging, 2014
View PDFchevron_right